Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Targeting RIPK1 for the treatment of human diseases

Open access
Degterev, Alexei, Ofengeim, Dimitry, Yuan, Junying·2019·Proceedings of the National Academy of Sciences

Abstract

Significance: RIPK1 plays a critical role in mediating deleterious responses downstream of TNFR1. RIPK1 inhibitors have been progressed successfully past human phase I clinical studies. This paper discusses why RIPK1 inhibitors present an opportunity for developing oral drugs for a range of human degenerative and inflammatory diseases, especially CNS pathologies, including ALS, Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, stroke, and lysosomal storage diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1901179116

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 124 references

Cited by

See all 408

Metadata

Authors
Degterev, A., Ofengeim, D., & Yuan, J.
Venue
Proceedings of the National Academy of Sciences
Published
2019-05-02
Volume
116
Issue
20
Pages
9714-9722
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2942761172
Cited by
408
References
124
FWCI
13.61
Type
journal article
Language
en
Open access
hybrid
Funders
HHS | NIH | National Institute on Aging (1R01AG047231)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting RIPK1 for the treatment of human diseases. https://app.cochat.ai/papers/10.1073/pnas.1901179116
The paper
Degterev, A., Ofengeim, D., & Yuan, J. (2019). Targeting RIPK1 for the treatment of human diseases. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1901179116

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.